Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is CG Oncology (CGON) Stock Down -9.88% Today?

Why Is CG Oncology (CGON) Stock Down -9.88% Today?

Key Takeaways

  • CG Oncology (CGON) fell 9.88% to $76.40 in late-morning trading Tuesday, down $8.38 from Monday's close of $84.78.
  • The primary catalyst was a valuation-driven downgrade: RBC Capital cut the shares to Sector Perform from Outperform, even as it lifted its price target to $97 from $80.
  • A secondary driver was aggressive profit-taking after Monday's 13.95% rally on pivotal PIVOT-006 Phase 3 data, a session in which the stock gapped to $92, peaked at $93.95 and then faded hard.
  • Sentiment was also dented by a regulatory timeline shift, with completion of the first BLA submission now targeted for the end of March 2027 rather than the fourth quarter of 2026.
  • Clinical-stage biotechnology peers traded broadly lower, adding sector pressure to a name that had just posted a record close.
  • News Significance Score: 63/100 - Pivotal Phase 3 data of major consequence, tempered by a decline nearly four times the stock's typical daily move.
  • Traders are watching the December 2 late-breaking PIVOT-006 presentation and 12-month durability data expected in December.
  • Readers seeking deeper detail can review Price Targets, Earnings and Forecast pages for the stock.
  • For AI-driven ideas across thousands of symbols, explore Trending AI Robots.

Opening Summary

CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesically delivered oncolytic immunotherapy intended to become a bladder-sparing backbone therapy for non-muscle invasive bladder cancer (NMIBC). The stock traded at $76.40 late Tuesday morning, a decline of 9.88% from the prior session's close of $84.78. The direction is clearly negative, and the pullback has erased the entire gain from Monday's data-driven surge. Markets are attributing the move to a downgrade tied to valuation, profit-taking after a record close, and a modestly extended regulatory timeline rather than to any setback in the underlying clinical dataset.

Analyst Downgrade Turns the Narrative to Valuation

The most immediate catalyst arrived before the opening bell, when RBC Capital Markets lowered its rating on CGON to Sector Perform from Outperform while simultaneously raising its price target to $97 from $80. That combination is the crux of the session's weakness: the analyst did not dispute the quality of the new data, but concluded that after a rally of roughly 25% from early-November levels, the risk-reward had become balanced.

The same desk had described the trial results as clearing "even the most optimistic bars," noting that a risk reduction above 50% had not featured in its most bullish conversations. When the bull case is fully reflected in the price, upgrades stop arriving and downgrades begin to matter far more than they otherwise would. Other firms remain constructive, with published targets clustering between $97 and $102, well above the current quote.

Profit-Taking After a Violent Data Rally

Monday's action carried its own warning. CGON opened at $92.00, traded as high as $93.95 — a fresh 52-week high — and then closed at $84.78, surrendering roughly 10% from the intraday peak on volume of about 9.9 million shares, some four times the typical daily turnover. That gap-and-fade pattern is characteristic of news-driven distribution, where early buyers hand stock to late arrivals.

Tuesday's decline extends that unwinding. The shares are now trading below Friday's close of $74.40 on an intraday basis at their lows, meaning the entire post-data revaluation has been reversed even though the trial outcome itself has not changed. With a market capitalization near $6.7 billion on roughly 88 million shares and no product revenue, the equity is highly sensitive to shifts in positioning.

Regulatory Timeline Extended

Alongside the efficacy data, the company said that, following FDA feedback, its initial BLA submission in BCG-unresponsive NMIBC will be broadened to include high-grade papillary-only disease in addition to carcinoma in situ. That broader label is strategically attractive, but incorporating the additional data pushes completion of the submission to before the end of March 2027, versus an earlier fourth-quarter 2026 target. A second BLA in intermediate-risk and high-grade Ta NMIBC is anticipated in the second quarter of 2027. For a pre-commercial company, a one-quarter slip in the first filing is a legitimate reason for some holders to trim exposure.

Market Context and Trading Activity

Volume is running above the stock's average pace but is a fraction of Monday's nearly 10 million shares, consistent with profit-taking rather than a fresh institutional repudiation of the thesis. The move was partly sympathetic: clinical-stage biotechnology names were broadly lower, with Summit Therapeutics (SMMT) plunging after an FDA Complete Response Letter and several other development-stage peers off 5% to 7% without company-specific news.

Technically, the stock has broken back below the roughly $81 breakout level it cleared on Monday and is testing the $74–$76 shelf built during the first half of November. The 52-week high of $93.95 now stands as the key resistance level, while a sustained hold above $74 would keep the medium-term uptrend intact.

News Significance Score

The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news paired with an extreme, rare price move. CG Oncology earns 63 out of 100.

The verified news is substantial: a registrational Phase 3 trial showing a 68% reduction in recurrence risk, a hazard ratio of 0.32 and a p-value below 0.0001, with no Grade 3 or higher treatment-related adverse events. Against a company of this size, that is a major, arguably near-transformative catalyst, though Tuesday's specific trigger — a valuation-based downgrade — is more modest. The price move is notable but not historic: at 9.88%, the decline is about 3.9 times the stock's typical daily move of roughly 2.6%, and a swing this large has occurred only twice in the past 60 sessions. Strong news and a moderately unusual decline combine into the mid-60s.

What Comes Next for CGON

The near-term calendar is dense. PIVOT-006 topline results will be presented as a late-breaking podium session at the Society of Urologic Oncology Annual Meeting on December 2, 2026, which will give specialists and investors their first full look at the dataset. December also brings 12-month durability data from BOND-003 Cohort P and CORE-008 Cohort CX, both of which speak to how durable responses are over time.

On the regulatory side, investors will focus on execution against the March 2027 BLA completion and the subsequent second filing in intermediate-risk disease. Fourth-quarter and full-year 2026 results are expected in late February 2027; the company ended the third quarter with roughly $984 million in cash and securities, funding operations into 2029 and removing near-term financing risk. Key uncertainties includeFDA review outcomes, competitive pressure from approved bladder-sparing therapies, the commercial build-out required ahead of launch, and the simple fact that a stock up more than 90% over twelve months can consolidate sharply on little new information.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view of automated strategies that are working right now. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but this section surfaces only the strongest performers under prevailing market conditions. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as volatility and leadership change. For readers tracking names like CG Oncology, it is a practical way to see which systematic approaches are currently keeping pace with the tape.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CGON

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


CGON in upward trend: price rose above 50-day moving average on November 06, 2026

CGON moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGON as a result. In 40 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 25 of 29 cases over the following month. The odds of a continued upward trend are 86%.

The 10-day moving average for CGON crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +20.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 119 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 89 of 99 cases where CGON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 39 cases where CGON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

CGON broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.545) is normal, around the industry mean (3.586). P/E Ratio (-28.249) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
400 Spectrum Center Drive
Phone
+1 949 409-3700
Employees
142
Web
https://www.cgoncology.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.